Protalix Biotherapeutics (PLX)

Protalix (PLX) Income Statement


Protalix Income Statement

Last quarter (Q1 2023), Protalix's total revenue was $9.59M, a decrease of -40.39% from the same quarter last year. In Q1, Protalix's net income was $-3.13M. See Protalix’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 22Dec 21Dec 20Dec 19Dec 18
Total Revenue
$ 32.52M$ 47.64M$ 38.35M$ 62.90M$ 54.69M$ 34.24M
Cost of Revenue
$ 8.08M$ -19.59M$ 16.35M$ 10.87M$ 10.89M$ 9.30M
Gross Profit
$ 18.28M$ 28.05M$ 22.00M$ 52.02M$ 43.80M$ 24.94M
Operating Expense
$ 29.39M$ 41.06M$ 42.46M$ 49.31M$ 54.52M$ 44.25M
Operating Income
$ -11.11M$ -13.01M$ -20.46M$ 2.71M$ -10.72M$ -19.31M
Net Non Operating Interest Income Expense
$ -252.00K-$ -7.12M$ -9.23M$ -7.56M$ -7.15M
Other Income Expense
$ 477.00K$ 1.38M----
Pretax Income
$ -11.84M$ -14.40M$ -27.58M$ -6.52M$ -18.28M$ -26.46M
Tax Provision
$ 195.00K$ 530.00K----
Earnings From Equity Interest Net Of Tax
Net Income Common Stockholders
$ -12.03M$ -14.93M$ -27.58M$ -6.52M$ -18.28M$ -26.46M
Basic EPS
$ -0.23$ -0.31$ -0.62$ -0.22$ -1.23$ -1.80
Diluted EPS
$ -0.23$ -0.31$ -0.62$ -0.22$ -1.23$ -1.80
Basic Average Shares
$ 154.31M$ 48.47M$ 44.14M$ 29.15M$ 14.84M$ 14.71M
Diluted Average Shares
$ 154.31M$ 48.47M$ 44.14M$ 29.15M$ 14.84M$ 14.71M
Dividend Per Share
Total Operating Income As Reported
Reported Normalized Basic E P S
Reported Normalized Diluted E P S
Rent Expense Supplemental
Total Expenses
$ 37.46M$ 21.47M$ 58.81M$ 60.19M$ 65.41M$ 53.55M
Net Income From Continuing And Discontinued Operation
$ -12.03M$ -14.93M$ -27.58M$ -6.52M$ -18.28M$ -26.46M
Normalized Income
$ -8.90M-$ -27.58M$ -6.52M$ -18.28M$ -26.46M
Interest Expense
$ 1.26M-$ 7.52M$ 9.67M$ 7.97M$ 7.68M
$ -10.57M$ -14.40M$ -20.06M$ 3.15M$ -10.31M$ -18.77M
$ -9.67M$ -13.00M$ -18.94M$ 4.45M$ -8.69M$ -17.10M
Currency in USD

Protalix Earnings and Revenue History

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis